Dr. Shilin N. Shukla Medical Oncology Oration Award - 2024

p a t h b r e a k i n g c o l l a t e r a l developments in all fields of oncology, including medical oncology.The data for adults aged 15 to 99 years indicate that the median survival time of the cancer patients has been constantly improving since 1990 (Figure 1).infrastructure, better research infrastructure, better regulatory framework, altogether better science and better translational research leading to better patient outcome.When I was with GCRI, in early 90s -targeted therapies and MAbs were like fairy tales or SciFi movies.At that time, IACC was renamed to ISMPO during a conference in Ahmedabad, IJKPOC was inaugurated in 1993 and UICC meeting was held in New Delhi.By the end of 90s, Rituximab and Trastuzumab were available and DRL-301 trial was initiated at GCRI.It was my first exposure to clinical trial (sponsored trials) and exposure to Quintiles (now IQVIA).IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health (Intercontinental Marketing Statistics Health), a leading healthcare data and analytics provider.IQVIA is an American multinational company serving the combined industries of health information technology and clinical research.It is a provider of biopharmaceutical d e v e l o p m e n t , p r o f e s s i o n a l c o n s u l t i n g a n d commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including investment strategy and management consulting services.